首页 › 期刊 › 医学 › Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases
出版商:Elsevier · ISSN:0003-4967, 1468-2060 · 国家/地区:GB · 类型:journal · 创刊:1939 · 官网:http://ard.bmj.com/
研究主题:Rheumatoid Arthritis Research and Therapies · Systemic Lupus Erythematosus Research · Spondyloarthritis Studies and Treatments · Systemic Sclerosis and Related Diseases · Autoimmune and Inflammatory Disorders Research
核心指标
- 影响因子(JCR 2025):24.000
- JCR 分区:Q1(RHEUMATOLOGY)
- 中科院分区(2025):医学 1区(Top);小类:RHEUMATOLOGY 风湿病学 1区
- 新锐分区(2026):医学 1区
- SJR:7.286(Q1)
- h-index:371
- i10 指数:13537
- 近两年篇均被引:1.42
- 载文量 73022 · 总被引 1243172
逐年趋势
- 近年影响因子:2021 28 → 2022 27.4 → 2023 20.3 → 2024 20.6 → 2025 24
- 近年 SJR:2021 5.37(Q1) → 2022 6.49(Q1) → 2023 6.14(Q1) → 2024 5.73(Q1) → 2025 7.29(Q1)
投稿参考
- 审稿周期:首次审稿意见平均约 0.9 个月
- 投稿人评价:3.2 分(24 条评价)
- 版面费(APC)约 $4870 USD(以期刊官网为准)
- 提供 LaTeX 投稿模板(elsarticle.cls)
- 提供投稿指南
同学科期刊推荐
- CA-A CANCER JOURNAL FOR CLINICIANS — IF 685.2 · JCR Q1 · 中科院1区(Top)
- The Lancet — IF 109.0 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Clinical Oncology — IF 94.6 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Drug Discovery — IF 91.2 · JCR Q1 · 中科院1区(Top)
- Kidney International Supplements — IF 89.6 · JCR Q1 · 中科院2区
- New England Journal of Medicine — IF 84.5 · JCR Q1 · 中科院1区(Top)
- Annals of Oncology — IF 80.4 · JCR Q1 · 中科院1区(Top)
- World Psychiatry — IF 65.8 · JCR Q1 · 中科院1区(Top)
常见问题
《Annals of the Rheumatic Diseases》的影响因子是多少?
根据 JCR 2025 年数据,《Annals of the Rheumatic Diseases》的最新影响因子(IF)为 24.000。
《Annals of the Rheumatic Diseases》是几区期刊?
《Annals of the Rheumatic Diseases》中科院分区(2025年版)为医学1区(Top 期刊),JCR 分区为 Q1。
《Annals of the Rheumatic Diseases》的审稿周期多久?
根据投稿经验数据,《Annals of the Rheumatic Diseases》首次审稿意见平均约 0.9 个月返回,实际周期因稿件而异。
《Annals of the Rheumatic Diseases》的版面费(APC)是多少?
根据 OpenAlex 收录的价目,《Annals of the Rheumatic Diseases》的文章处理费(APC)约为 $4870 美元。实际费用与豁免政策请以期刊官网为准。
本刊近期代表论文
- EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update (2025 · 被引 67)
- Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update (2025 · 被引 32)
- Spatial multiomics decipher fibroblast–macrophage dynamics in systemic sclerosis (2025 · 被引 25)
- Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial (2025 · 被引 21)
- Primary Sjögren’s Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI) (2025 · 被引 20)
- EULAR/ACR classification criteria for paediatric chronic nonbacterial osteomyelitis (CNO) (2025 · 被引 16)